INTRODUCTION
Antiretroviral drug combinations, which include 2-3 nucleoside reverse transcriptase inhibitors (NRTIs) and drugs of other classes, constitute standard-of-care therapy for individuals infected with the HIV-1 [1 && ,2 & ]. Each year in the United States approximately 10 000 HIV-1-infected pregnant women receive antiretroviral drug combinations to prevent mother-to-child HIV-1 transmission (MTCT). This approach has saved many thousands of children worldwide from HIV-1 infection [2 & ]. However, the HIV-1-exposed uninfected (HEU) children born to HIV-1-infected mothers are susceptible to manifestations of genotoxicity and mitochondrial toxicity likely due to antiretroviral drug exposures occurring while in utero. This is not surprising as, in adult patients, mitochondrial toxicities may limit NRTI use [3] , and the NRTI zidovudine (AZT) is a transplacental carcinogen in mice [4] .
In common with normal nucleosides, NRTIs become phosphorylated and incorporated into host nuclear and mitochondrial DNA (mtDNA), as well as the cDNA of the virus [5] . However, the lack of a 3'-ribose-OH results in arrest of DNA replication, which has been documented in many species and cell types. The consequences to the cell include shortened DNA, mutagenesis, shortened telomeres, centrosome/spindle abnormalities, and aneuploidy as well as transplacentally induced tumorigenesis in mice [4, 6, 7] . Whereas most HEU children, now in their teenage years, show no evidence of increased tumor risk, one study reported an elevated risk (standardized incidence ratio 3.1, P ¼ 0.05) of central nervous tumors in a few infants born to HIV-1infected mothers receiving the NRTI combination AZT/didanosine during pregnancy [8] . Transplacental AZT exposure has produced similar levels of AZT-DNA incorporation in newborn fetal tissues from mice and monkeys, and blood and placenta from humans [5] . Because the mice exposed to AZT in utero developed liver and lung tumors in middle age [4] , there is a concern that NRTIs might be human transplacental carcinogens.
Mitochondrial dysfunction induced by NRTIs is considered to result from direct inhibition of the mitochondrial polymerase g, as well as drug-DNA incorporation and arrest of DNA replication [9, 10] . Clinical manifestations of NRTI use in human pregnancy [11] , in HEU children, include neurological and cardiac effects evident in a subset of children. However, morphological and molecular manifestations of mitochondrial compromise, which have been frequently observed in children exposed to NRTIs in utero [12] [13] [14] , include aberrant levels of mtDNA, mitochondrial morphological damage by electron microscopy, and altered oxidative phosphorylation.
This review will focus on genotoxicity and mitochondrial toxicity evident in HEU children born to HIV-1-infected mothers given antiretroviral drugs for MTCT, and in parallel in Erythrocebus patas (patas) monkey offspring given human-equivalent antiretroviral drug protocols. The patas NRTI metabolism and placentation are similar to humans [15] , and because these monkeys do not become infected with an immunodeficiency virus, evaluation of drug toxicity can take place with no confounding retroviral effects.
GENOTOXICITY IN PATAS MONKEYS
The incorporation of NRTIs into host nuclear DNA has been shown to occur in many species and cultured cells [5] . With transplacental exposures, DNA incorporation of the most commonly used NRTs, AZT, and lamivudine (3TC), has been found in human blood cell and placental DNA, as well as in DNA from many organs of monkey and mouse offspring [5] . Incorporation of NRTIs into DNA has been shown to produce various manifestations of chromosomal distress, including centrosomal amplification (>2 centrosomes/cell), micronucleus formation, and micronuclei containing whole chromosomes (MNþC), indicative of aneuploidy in the parent cell [7] .
To examine these end points in the patas, pregnant dams were given 10 weeks of daily humanequivalent NRTI dosing that included AZT/3TC, AZT/3TC and abacavir (ABC), or AZT/3TC and the non-NRTI nevirapine (NVP), and the results were published previously. Offspring were evaluated at birth, 1, or 3 years of age (equivalent to 5-year and 15-year-old humans). To model human clinical exposures, the 1-year and 3-year-old patas received 6 weeks of NRTI dosing postbirth. Mesenchymal cells were taken from bone marrow of patas at birth, 1 and 3 years of age, cultured and scored. Compared with unexposed controls, significant increases in centrosomal amplification and micronucleus were found in offspring exposed in utero to AZT/3TC when examined at birth, offspring exposed in utero to AZT/3TC/ABC when examined at 1 and 3 years, and offspring exposed to AZT/3TC/NVP when examined at 3 years [16 && ]. Of particular importance is the MNþC end point ( Fig. 1a ) because aneuploidy or chromosomal loss may lead to cancer. Therefore, Fig. 1a shows MNþC data from the patas study described above [16 && ]. Offspring in all of the NRTI-treated groups, AZT/3TC
KEY POINTS
The NRTIs AZT and 3TC become incorporated into offspring nuclear and mtDNA when women and patas monkeys are treated with similar protocols during pregnancy.
Offspring of both species have blood cell aneuploidy at birth, and this persists in the patas for 3 years (equivalent to a 15-year-old human).
Mitochondrial morphological damage and mtDNA abnormalities are similar in NRTI-exposed patas and humans at birth, and persist in patas heart and brain up to 3 years of age.
Depletion of mtDNA (50%) was found in brains of 1-year-old patas exposed in utero to mixtures containing two NRTIs.
The data suggest that some HIV-1-uninfected infants born to HIV-1-infected mothers receiving antiretroviral drug therapy during pregnancy sustain toxicities that may produce adverse consequences later in life.
at birth, AZT/3TC/ABC at 1 year, and AZT/3TC/ABC and AZT/3TC/NVP at 3 years, showed increased MNþC compared with the unexposed controls (P < 0.05). Therefore, these drugs damage DNA indirectly by altering chromosome integrity and producing centrosomal postmitosis aneuploidy. The long-term persistence of all these genotoxic events is consistent with a potential increased cancer risk in primates, and the transplacental tumorigenicity observed in offspring of mice exposed to AZT during gestation [4] .
GENOTOXICITY IN CHILDREN
The question of chromosomal aberration/aneuploidy in children born to HIV-infected mothers was addressed by Andre-Schmutz et al. [17 && ]. Cord blood CD34 [À] cells were collected from 15 HIV-1infected mothers receiving AZT-based combinations, and 12 uninfected controls. Chromosomes were scored in 30 metaphases from each infant, to determine individual aneuploidy rate. A significant (P < 0.001) increase in aneuploidy rate was seen in the HIV-1-infected pregnancies compared with the controls (Fig. 1b) , again supporting the hypothesis that aneuploidy is a consequence of transplacental NRTI exposure in primates, and an indicator of genotoxicity that may be associated with increased cancer risk.
MITOCHONDRIAL TOXICITY
Mitochondrial toxicity in children born to HIV-1infected mothers receiving NRTI therapy has been hypothesized and observed for some time [11] . The cardiac insufficiency, skeletal muscle weakness, and neurological effects seen in adult HIV-1-infected patients were recognized to be the result of mitochondrial compromise partially caused by chronic NRTI therapy. Early on, it was considered that the duration of pregnancy was too short a time for NRTIinduced mitochondrial dysfunction to appear in the fetus. However, reports of mitochondrial morphological damage in umbilical cord [13] , depletion of infant mtDNA [12] , reduction in heart left ventricular muscle mass [18, 19] , and neurological compromise [14] , all indicated that transplacental use of antiretroviral drugs is not without consequences for the developing fetus.
CLINICAL MITOCHONDRIAL DYSFUNCTION
Clinically evident mitochondrial dysfunction is seen infrequently in HEU children. However, cardiac effects have been reported, including reduced cardiac growth in HIV-1-infected [19] and HEU children [18,20 && ]. In HEU children, transplacental antiretroviral drug exposure was associated with significantly reduced left ventricular mass and left cells from 15 AZT-exposed pregnancies and 12 uninfected pregnancies, were karyotyped. The percentage of cells with aneuploidy, based on 30 metaphases from each individual, was significantly higher in the AZT-exposed group compared to the unexposed group (P 0.001). 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; MNþC micronuclei containing whole chromosomes; NVP, nevirapine.
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ventricular septal thickness, compared with children from uninfected mothers, and girls were more frequently affected than boys. In addition, when biomarkers of cardiac integrity were examined in 338 HEU children (median age 4.3 years), 51% had at least one elevated biomarker [21 && ]. Other clinical manifestations of mitochondrial dysfunction include blood lactate elevation, which is infrequent in HEU children [22] , small reductions in neurodevelopmental and cognitive outcomes in HEU children [23 & ], and increased susceptibility to infections [24 & ], which, along with altered innate immune development in the first few months of life [25 & ], suggest a compromised immune response in HEU children.
BIOMARKERS OF MITOCHONDRIAL COMPROMISE
Biomarkers indicative of mitochondrial and molecular compromise have been observed in human infants and in patas monkey offspring exposed in utero to NRTIs. Unlike the clinical mitochondrial dysfunction, which is seen infrequently, these manifestations have been found frequently in the human and patas monkey infants examined. Mitochondrial morphology, observed by electron microscopy, typically shows compromise of the mitochondrial membrane, resulting in rounding of the organelle, influx of proteolytic enzymes, and gradual erosion of the cristae [26] . Quantitative real-time PCR (qRT-PCR) based methods are most commonly used to measure mtDNA [27] , and whereas frequently NRTI-exposure induces mtDNA depletion [13, 28] , compensatory mtDNA amplification has also been observed [29] . Both damaged mitochondria and depletion of mtDNA have been observed in the heart, brain, liver and placenta of NRTI-exposed patas monkey offspring at birth and 1 year of age [26, 30, 31] , and there is persistence of mitochondrial morphological damage in brain and heart of 3-year-old patas.
SOURCE OF MITOCHONDRIAL DYSFUNCTION
In children born to HIV-1-infected mothers, it has been difficult to ascertain whether the presence of maternal HIV-1 infection or the antiretroviral drugs given to prevent MTCT, or both, are major causative events. It has been possible to address this issue using umbilical cord and cord blood, which are available from both human and monkey pregnancies [26] . Combinations of AZT/3TC and AZT/didanosine were compared in HIV-1-infected pregnant women and in uninfected patas dams. Daily dosing was equivalent in both species, but the patas received drug for the last 50% of gestation, whereas the human recommendation is for drug to be given for the last 6 months of pregnancy. At birth, the degree of NRTI-induced mitochondrial morphological damage, by electron microscopy, was similar in the umbilical cord endothelial cells of both species, and similar reductions in cord blood mtDNA quantity were found in the NRTI-exposed human and monkey offspring, compared with the unexposed controls [26] . These studies show that, in the absence of virus, NRTIs may produce significant mitochondrial compromise.
MITOCHONDRIAL DNA QUANTITATION
As mentioned previously, mtDNA quantity is often depleted in the presence of NRTI exposures, but it can also be abnormally increased in HEU children.
The actual values obtained may vary based on the population, the assay conditions, the tissue used, and the region of mtDNA amplified. Figure 2 shows previously unpublished data demonstrating depletion in placental mtDNA from HIV-1-infected women (n ¼ 41), compared with placental DNA from uninfected women (n ¼ 48). These samples were collected in Medellin, Colombia, and all of the HIV-1-infected women received antiretroviral drug therapy during pregnancy, or at the time of delivery, or for both. The placental mtDNA was quantified by a hybrid capture chemiluminescence assay (HCCA) [31] . There was no difference between the two groups by Wilcoxon rank-sum test (P ¼ 0.57). However, taking into consideration the fact that all of the samples from infected mothers had less mtDNA than the blood bank control sample (considered 100%), and 13 of the 48 samples from uninfected women had higher values than any of those from the 41 infected patients, the groups can be compared by dichotomizing values above and below the control, which is set at 100%. This analysis could be biased because the control value was a blood bank sample, and the comparison determined post hoc. However, the adjusted P value by Fisher's exact test was P < 0.01, indicating significantly lower levels of mtDNA in the placentas from HIV-1-infected women, compared with uninfected women.
In another study [12] , mtDNA was examined in cord blood taken at birth and peripheral blood taken at 1 and 2 years of age, from infants born to uninfected mothers, infants born to HIV-1-infected mothers taking no antiretroviral drugs, and infants born to HIV-1-infected mothers taking AZT during pregnancy. Compared with the unexposed controls, there was mtDNA depletion in the infants exposed in utero to HIV-1 alone. However, even lower mtDNA levels were observed in the infants born to HIV-1infected mothers who received AZT. Therefore, both the maternal HIV-1 infection and NRTI exposures contributed to the observed reduction in mtDNA levels in cord and peripheral blood [12] .
LONG-TERM PERSISTENCE OF ANTIRETROVIRAL-INDUCED TRANSPLACENTAL EFFECTS
The issue of the long-term persistence of the NRTIinduced transplacental effects cannot be readily addressed in children, but can be examined in the patas monkey model. A patas monkey at 3 years of age is developmentally equivalent to a 15-year-old human adolescent, and a 1-year-old patas is similar to a 5-year-old child. The human-equivalent daily doses of antiretroviral drug given to patas dams for the last 10 weeks of gestation were designed to model the recommended 6 months of therapy for prevention of human MTCT. As mentioned previously, the long-term persistence of aneuploidy and other genotoxic effects in the patas infants extended to at least 3 years of age [16 && ]. In human children, aneuploidy was observed at birth [17 && ] but persistence at later ages has not been investigated.
For the analysis of mitochondrial toxicity, echocardiographic analysis revealed reduced left ventricular muscle mass in some HEU children up to 5 years of age [20 && ], but the long-term cardiac consequences will only become apparent as the children age. The monkey studies may be more informative as the offspring organs are available for study at any age. Using combinations of two NRTIs, we showed Table 1 . Comparison of biomarkers of genotoxicity and mitochondrial toxicity, for human infants exposed in utero to antiretroviral drugs, and patas offspring exposed transplacentally for the last half of gestation to human-equivalent antiretroviral-drug protocols FIGURE 2. Analysis of mtDNA for placental DNA from 48 uninfected pregnancies, and 41 pregnancies in which the mother was HIV-1-infected and received antiretroviral therapy. mtDNA quantity was determined by hybrid capture chemiluminescence assay (HCCA) [31] in the 89 samples of placenta DNA and in blood bank DNA, which was designated 100% and used as a control. Dichotomized using the control, values from HIV-1-infected/ARV-exposed pregnancies were lower than those from uninfected pregnancies by Fisher's Exact test (P < 0.01).
depletion of mtDNA at birth in patas heart, skeletal muscle, brain, and liver [30, 31] . Furthermore, at 1 year of age, the brain mtDNA levels were only 50% of those found in the unexposed controls, whereas the heart mtDNA had increased in a compensatory fashion, largely due to the abnormal proliferation of damaged mitochondria [30, 31] . Finally, ongoing electron microscopy studies with the patas show no reduction in the degree of damage induced by AZT/3TC/ABC or AZT/3TC/NVP in heart and brain at 1 and 3 years of age, indicating that the damage is not readily reversible.
CONCLUSION
Use of antiretroviral drugs in human pregnancy constitutes one of the most successful strategies in the war on HIV-1/AIDS, as many thousands of children worldwide are protected from HIV-1 infection. There are, however, increasing numbers of HEU children, who have developed in utero under the influence of these drugs. HEU children typically function without problem, although some clinical studies, and the biomarker and monkey evidence presented here (Table 1) , suggest that there may be progressive changes that will compromise important organs, such as heart and brain, as aging occurs.
